PL3770160T3 - Środki kontrastowe na bazie PCTA zawierające gadolin - Google Patents

Środki kontrastowe na bazie PCTA zawierające gadolin

Info

Publication number
PL3770160T3
PL3770160T3 PL20193824.8T PL20193824T PL3770160T3 PL 3770160 T3 PL3770160 T3 PL 3770160T3 PL 20193824 T PL20193824 T PL 20193824T PL 3770160 T3 PL3770160 T3 PL 3770160T3
Authority
PL
Poland
Prior art keywords
pcta
contrast agents
agents containing
based contrast
containing gadolinium
Prior art date
Application number
PL20193824.8T
Other languages
English (en)
Inventor
Roberta Napolitano
Luciano Lattuada
Zsolt Baranyai
Nicole GUIDOLIN
Giuseppe Marazzi
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63165233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3770160(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of PL3770160T3 publication Critical patent/PL3770160T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL20193824.8T 2018-08-06 2019-08-06 Środki kontrastowe na bazie PCTA zawierające gadolin PL3770160T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18187422 2018-08-06

Publications (1)

Publication Number Publication Date
PL3770160T3 true PL3770160T3 (pl) 2023-05-29

Family

ID=63165233

Family Applications (3)

Application Number Title Priority Date Filing Date
PL22205189.8T PL4151637T3 (pl) 2018-08-06 2019-08-06 Środki kontrastowe na bazie PCTA zawierające gadolin
PL20193824.8T PL3770160T3 (pl) 2018-08-06 2019-08-06 Środki kontrastowe na bazie PCTA zawierające gadolin
PL19753296T PL3687994T3 (pl) 2018-08-06 2019-08-06 Środki kontrastowe na bazie pcta zawierające gadolin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL22205189.8T PL4151637T3 (pl) 2018-08-06 2019-08-06 Środki kontrastowe na bazie PCTA zawierające gadolin

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19753296T PL3687994T3 (pl) 2018-08-06 2019-08-06 Środki kontrastowe na bazie pcta zawierające gadolin

Country Status (14)

Country Link
US (3) US10973934B2 (pl)
EP (4) EP4491199A3 (pl)
JP (1) JP7558146B2 (pl)
KR (2) KR102815156B1 (pl)
CN (4) CN119930615A (pl)
AU (1) AU2019319599B2 (pl)
BR (1) BR112021001102B1 (pl)
CA (1) CA3105610C (pl)
DK (3) DK3687994T3 (pl)
ES (3) ES2841070T3 (pl)
FI (2) FI4151637T3 (pl)
PL (3) PL4151637T3 (pl)
PT (3) PT3687994T (pl)
WO (1) WO2020030618A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102815156B1 (ko) * 2018-08-06 2025-05-30 브라코 이미징 에스.피.에이. 가돌리늄 함유 pcta-기반 조영제
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
EP4512815A3 (en) * 2019-09-03 2025-05-07 GE Healthcare AS Manganese chelate isomers
FI4143153T3 (fi) * 2020-07-16 2023-12-20 Guerbet Sa Menetelmä 2-bromiglutaarihapon diesterien synteesiä varten
KR20230041007A (ko) * 2020-07-17 2023-03-23 게르브 Pcta로부터 유도된 킬레이팅 리간드의 제조 방법
WO2024046833A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046831A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046832A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
EP4582432A4 (en) * 2022-09-01 2025-12-10 Theranocure Co Ltd Novel compound and mri contrast agent comprising same
KR102845061B1 (ko) * 2022-09-01 2025-08-13 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
US20260087710A1 (en) 2022-09-05 2026-03-26 Bayer Aktiengesellschaft Generation of artificial contrast-enhanced radiological images
WO2024083466A1 (de) 2022-10-17 2024-04-25 Bayer Aktiengesellschaft Automatisches analysieren von radiologischen aufnahmen
EP4369353A1 (de) 2022-11-12 2024-05-15 Bayer Aktiengesellschaft Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4471710B1 (de) 2023-05-30 2025-12-17 Bayer Aktiengesellschaft Erkennen von artefakten in synthetischen medizinischen aufnahmen
US20240404255A1 (en) 2023-06-05 2024-12-05 Bayer Aktiengesellschaft Generation of artificial contrast-enhanced radiological images
EP4475137B1 (de) 2023-06-05 2025-12-03 Bayer Aktiengesellschaft Erzeugen von künstlichen kontrastverstärkten radiologischen aufnahmen
US20250045926A1 (en) 2023-07-25 2025-02-06 Bayer Aktiengesellschaft Detection of artifacts in synthetic images
TW202510874A (zh) * 2023-09-01 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種大環化合物及其用途
EP4567716A1 (en) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Generating synthetic representations
EP4567715A1 (en) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Generating synthetic representations
WO2025190828A1 (en) 2024-03-15 2025-09-18 Bayer Aktiengesellschaft Correction of an mri image
EP4664393A1 (de) 2024-06-10 2025-12-17 Bayer Aktiengesellschaft Erzeugen von synthetischen kontrastverstärkten radiologischen aufnahmen
WO2026027591A1 (en) 2024-07-31 2026-02-05 Bracco Imaging Spa Synthesis of an intermediate of a gadolinium-based contrast agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0992245A1 (en) 1998-09-16 2000-04-12 Goldham Bioglan Pharma GmbH Radio-contrast agents
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
FR2836916B1 (fr) 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
FR2883562B1 (fr) 2005-03-24 2009-02-27 Guerbet Sa Chelates lipophiles et leur utilisation en imagerie
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
HRP20170874T4 (hr) 2013-04-26 2022-09-02 Guerbet Formulacija kontrastnog medija i odgovarajući postupak dobivanja
KR102815156B1 (ko) * 2018-08-06 2025-05-30 브라코 이미징 에스.피.에이. 가돌리늄 함유 pcta-기반 조영제
FR3091873B1 (fr) 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification

Also Published As

Publication number Publication date
EP3770160B1 (en) 2022-11-23
CN119954806A (zh) 2025-05-09
ES2938015T3 (es) 2023-04-03
BR112021001102B1 (pt) 2022-12-20
DK3687994T3 (da) 2021-01-25
JP7558146B2 (ja) 2024-09-30
KR102815156B1 (ko) 2025-05-30
AU2019319599B2 (en) 2024-01-04
US10973934B2 (en) 2021-04-13
EP3770160A1 (en) 2021-01-27
ES2841070T3 (es) 2021-07-07
KR20210041566A (ko) 2021-04-15
DK3770160T3 (da) 2023-02-20
CN119930615A (zh) 2025-05-06
EP3687994B1 (en) 2020-11-04
CN112533921A (zh) 2021-03-19
EP4151637B1 (en) 2025-01-22
US20240366802A1 (en) 2024-11-07
CA3105610C (en) 2024-05-28
PT4151637T (pt) 2025-03-26
WO2020030618A1 (en) 2020-02-13
EP4491199A3 (en) 2025-04-16
FI4151637T3 (fi) 2025-03-28
PL3687994T3 (pl) 2021-05-04
FI3770160T3 (fi) 2023-03-16
PT3687994T (pt) 2020-12-07
EP4151637A1 (en) 2023-03-22
US20200376145A1 (en) 2020-12-03
EP3687994A1 (en) 2020-08-05
AU2019319599A1 (en) 2021-01-28
CN119039292A (zh) 2024-11-29
PL4151637T3 (pl) 2025-04-28
EP4491199A2 (en) 2025-01-15
JP2021533165A (ja) 2021-12-02
CA3105610A1 (en) 2020-02-13
PT3770160T (pt) 2023-02-21
CN112533921B (zh) 2025-02-21
JP2024178261A (ja) 2024-12-24
ES3015456T3 (en) 2025-05-05
US12036289B2 (en) 2024-07-16
BR112021001102A2 (pt) 2021-04-20
KR20250079243A (ko) 2025-06-04
DK4151637T3 (da) 2025-03-31
US20210196840A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
PL3770160T3 (pl) Środki kontrastowe na bazie PCTA zawierające gadolin
IL286833A (en) Compositions containing brazzein
MA47609A (fr) Anticorps anti-il31 à usage vétérinaire
LT3810602T (lt) Junginiai
EP3906029A4 (en) INHIBITORS OF MENIN-MLL INTERACTION
PL3910421T3 (pl) Kaseta na toner
PL3629098T3 (pl) Kaseta wywołująca
DK3866931T3 (da) Forbindelser indeholdende deuterium
EP3338142A4 (en) INK DEVELOPER
LT3781200T (lt) Chelatintų radionuklidų antikūnai
EP3803743A4 (en) CONSISTENT TOKENIZATION INDEPENDENT OF THE SOURCE
PL3662894T3 (pl) Nanocząstki zawierające takrolimus
CL2018002822S1 (es) Envase
EP3823902C0 (de) Behälter
HUE065134T2 (hu) Vegyületek
EP3857311C0 (en) DEVELOPMENT CARTRIDGE
DK3569989T3 (da) Fluidmåler
EP3763628A4 (en) CONTAINER
EP3482729A4 (en) Pull-up type absorbent article
PL3856106T3 (pl) Strój
EP3819231C0 (en) Application container
EP3658993A4 (en) DEVELOPMENT CARTRIDGE
EP3704032C0 (de) Behälter
EP4055005A4 (en) Liquid melphalan composition
DK3659700T3 (da) Magnetisk koblet væskeblander